Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer

Arnulf Stenzl, Maximilian Burger, Yves Fradet, Lance A. Mynderse, Mark S. Soloway, J. Alfred Witjes, Martin Kriegmair, Alexander Karl, Yu Shen, H. Barton Grossman

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

Purpose We assessed the impact that improved detection of nonmuscle invasive bladder cancer with hexaminolevulinate fluorescence cystoscopy may have on early recurrence rates. Materials and Methods This prospective, randomized study enrolled 814 patients suspected of having bladder cancer at increased risk for recurrence. All patients underwent white light cystoscopy and mapping of lesions, followed by transurethral resection of the bladder when indicated. Patients in the fluorescence group also received intravesical hexaminolevulinate solution at least 1 hour before cystoscopy to induce fluorescence of cancerous lesions, and underwent additional inspection with blue light before and after transurethral resection of the bladder. Adjuvant intravesical therapy was based on risk. Followup cystoscopy at 3, 6 and 9 months was conducted with white light. Results Detection was performed as a within patient comparison in the fluorescence group. In this group 286 patients had at least 1 Ta or T1 tumor (intent to treat). In 47 patients (16%) at least 1 of the tumors was seen only with fluorescence (p = 0.001). During the 9-month followup (intent to treat) there was tumor recurrence in 128 of 271 patients (47%) in the fluorescence group and 157 of 280 (56%) in the white light group (p = 0.026). The relative reduction in recurrence rate was 16%. Conclusions Hexaminolevulinate fluorescence cystoscopy significantly improves the detection of Ta and T1 lesions and significantly reduces the rate of tumor recurrence at 9 months.

Original languageEnglish
Pages (from-to)1907-1913
Number of pages7
JournalJournal of Urology
Volume184
Issue number5
DOIs
StatePublished - Nov 1 2010
Externally publishedYes

Fingerprint

Cystoscopy
Urinary Bladder Neoplasms
Fluorescence
Recurrence
Light
Neoplasms
Urinary Bladder
5-aminolevulinic acid hexyl ester
Prospective Studies

Keywords

  • 5-aminolevulinic acid hexyl ester
  • Cystoscopy
  • Fluorescence
  • Recurrence
  • Urinary bladder neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Stenzl, A., Burger, M., Fradet, Y., Mynderse, L. A., Soloway, M. S., Witjes, J. A., ... Grossman, H. B. (2010). Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. Journal of Urology, 184(5), 1907-1913. https://doi.org/10.1016/j.juro.2010.06.148

Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. / Stenzl, Arnulf; Burger, Maximilian; Fradet, Yves; Mynderse, Lance A.; Soloway, Mark S.; Witjes, J. Alfred; Kriegmair, Martin; Karl, Alexander; Shen, Yu; Grossman, H. Barton.

In: Journal of Urology, Vol. 184, No. 5, 01.11.2010, p. 1907-1913.

Research output: Contribution to journalArticle

Stenzl, A, Burger, M, Fradet, Y, Mynderse, LA, Soloway, MS, Witjes, JA, Kriegmair, M, Karl, A, Shen, Y & Grossman, HB 2010, 'Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer', Journal of Urology, vol. 184, no. 5, pp. 1907-1913. https://doi.org/10.1016/j.juro.2010.06.148
Stenzl, Arnulf ; Burger, Maximilian ; Fradet, Yves ; Mynderse, Lance A. ; Soloway, Mark S. ; Witjes, J. Alfred ; Kriegmair, Martin ; Karl, Alexander ; Shen, Yu ; Grossman, H. Barton. / Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. In: Journal of Urology. 2010 ; Vol. 184, No. 5. pp. 1907-1913.
@article{8bb1b2019ec54927ad827e4f6c5ed9d1,
title = "Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer",
abstract = "Purpose We assessed the impact that improved detection of nonmuscle invasive bladder cancer with hexaminolevulinate fluorescence cystoscopy may have on early recurrence rates. Materials and Methods This prospective, randomized study enrolled 814 patients suspected of having bladder cancer at increased risk for recurrence. All patients underwent white light cystoscopy and mapping of lesions, followed by transurethral resection of the bladder when indicated. Patients in the fluorescence group also received intravesical hexaminolevulinate solution at least 1 hour before cystoscopy to induce fluorescence of cancerous lesions, and underwent additional inspection with blue light before and after transurethral resection of the bladder. Adjuvant intravesical therapy was based on risk. Followup cystoscopy at 3, 6 and 9 months was conducted with white light. Results Detection was performed as a within patient comparison in the fluorescence group. In this group 286 patients had at least 1 Ta or T1 tumor (intent to treat). In 47 patients (16{\%}) at least 1 of the tumors was seen only with fluorescence (p = 0.001). During the 9-month followup (intent to treat) there was tumor recurrence in 128 of 271 patients (47{\%}) in the fluorescence group and 157 of 280 (56{\%}) in the white light group (p = 0.026). The relative reduction in recurrence rate was 16{\%}. Conclusions Hexaminolevulinate fluorescence cystoscopy significantly improves the detection of Ta and T1 lesions and significantly reduces the rate of tumor recurrence at 9 months.",
keywords = "5-aminolevulinic acid hexyl ester, Cystoscopy, Fluorescence, Recurrence, Urinary bladder neoplasms",
author = "Arnulf Stenzl and Maximilian Burger and Yves Fradet and Mynderse, {Lance A.} and Soloway, {Mark S.} and Witjes, {J. Alfred} and Martin Kriegmair and Alexander Karl and Yu Shen and Grossman, {H. Barton}",
year = "2010",
month = "11",
day = "1",
doi = "10.1016/j.juro.2010.06.148",
language = "English",
volume = "184",
pages = "1907--1913",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer

AU - Stenzl, Arnulf

AU - Burger, Maximilian

AU - Fradet, Yves

AU - Mynderse, Lance A.

AU - Soloway, Mark S.

AU - Witjes, J. Alfred

AU - Kriegmair, Martin

AU - Karl, Alexander

AU - Shen, Yu

AU - Grossman, H. Barton

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Purpose We assessed the impact that improved detection of nonmuscle invasive bladder cancer with hexaminolevulinate fluorescence cystoscopy may have on early recurrence rates. Materials and Methods This prospective, randomized study enrolled 814 patients suspected of having bladder cancer at increased risk for recurrence. All patients underwent white light cystoscopy and mapping of lesions, followed by transurethral resection of the bladder when indicated. Patients in the fluorescence group also received intravesical hexaminolevulinate solution at least 1 hour before cystoscopy to induce fluorescence of cancerous lesions, and underwent additional inspection with blue light before and after transurethral resection of the bladder. Adjuvant intravesical therapy was based on risk. Followup cystoscopy at 3, 6 and 9 months was conducted with white light. Results Detection was performed as a within patient comparison in the fluorescence group. In this group 286 patients had at least 1 Ta or T1 tumor (intent to treat). In 47 patients (16%) at least 1 of the tumors was seen only with fluorescence (p = 0.001). During the 9-month followup (intent to treat) there was tumor recurrence in 128 of 271 patients (47%) in the fluorescence group and 157 of 280 (56%) in the white light group (p = 0.026). The relative reduction in recurrence rate was 16%. Conclusions Hexaminolevulinate fluorescence cystoscopy significantly improves the detection of Ta and T1 lesions and significantly reduces the rate of tumor recurrence at 9 months.

AB - Purpose We assessed the impact that improved detection of nonmuscle invasive bladder cancer with hexaminolevulinate fluorescence cystoscopy may have on early recurrence rates. Materials and Methods This prospective, randomized study enrolled 814 patients suspected of having bladder cancer at increased risk for recurrence. All patients underwent white light cystoscopy and mapping of lesions, followed by transurethral resection of the bladder when indicated. Patients in the fluorescence group also received intravesical hexaminolevulinate solution at least 1 hour before cystoscopy to induce fluorescence of cancerous lesions, and underwent additional inspection with blue light before and after transurethral resection of the bladder. Adjuvant intravesical therapy was based on risk. Followup cystoscopy at 3, 6 and 9 months was conducted with white light. Results Detection was performed as a within patient comparison in the fluorescence group. In this group 286 patients had at least 1 Ta or T1 tumor (intent to treat). In 47 patients (16%) at least 1 of the tumors was seen only with fluorescence (p = 0.001). During the 9-month followup (intent to treat) there was tumor recurrence in 128 of 271 patients (47%) in the fluorescence group and 157 of 280 (56%) in the white light group (p = 0.026). The relative reduction in recurrence rate was 16%. Conclusions Hexaminolevulinate fluorescence cystoscopy significantly improves the detection of Ta and T1 lesions and significantly reduces the rate of tumor recurrence at 9 months.

KW - 5-aminolevulinic acid hexyl ester

KW - Cystoscopy

KW - Fluorescence

KW - Recurrence

KW - Urinary bladder neoplasms

UR - http://www.scopus.com/inward/record.url?scp=77957834145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957834145&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2010.06.148

DO - 10.1016/j.juro.2010.06.148

M3 - Article

C2 - 20850152

AN - SCOPUS:77957834145

VL - 184

SP - 1907

EP - 1913

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -